Brady Nicholas, Chuntova Polly, Bade Lindsey K, Schwertfeger Kathryn L
Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455.
Molecular, Cellular, Developmental Biology and Genetics Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455.
Expert Rev Endocrinol Metab. 2013 Jul;8(4):391-402. doi: 10.1586/17446651.2013.811910.
Fibroblast growth factor receptor (FGFR) signaling is a vital component of both embryonic and postnatal mammary gland development, which has prompted researchers to investigate both its relevance to breast cancer and its potential as a therapeutic target. Deregulated FGFR signaling during breast cancer occurs through various mechanisms, including amplification of the receptor genes, aberrant ligand expression, receptor mutations and translocations. Recent experimental outcomes involving both animal models and human breast cancer cell lines have led to the initiation of multiple early clinical trials investigating the safety and efficacy of small molecule FGFR inhibitors. In this article we review both the most recent discoveries and the need for further investigation of the mechanisms through which FGF/FGFR signaling has emerged as an oncogenic driver.
成纤维细胞生长因子受体（FGFR）信号传导是胚胎期和出生后乳腺发育的重要组成部分，这促使研究人员探究其与乳腺癌的相关性以及作为治疗靶点的潜力。乳腺癌中FGFR信号传导失调通过多种机制发生，包括受体基因扩增、异常配体表达、受体突变和易位。最近涉及动物模型和人乳腺癌细胞系的实验结果已促使开展多项早期临床试验，以研究小分子FGFR抑制剂的安全性和有效性。在本文中，我们综述了最新发现以及进一步研究FGF/FGFR信号传导成为致癌驱动因素的机制的必要性。
